Atterx BioTherapeutics Obtains $700,000 New Round

  • Feed Type
  • Date
    2/10/2015
  • Company Name
    Atterx BioTherapeutics
  • Mailing Address
    505 South Rosa Road Madison, WI 53719 USA
  • Company Description
    Atterx has developed two products to fight multi-drug resistant, Gram negative bacteria. Our first product, C-1205 utilizes bacterial interference technology to prevent catheter associated urinary tract infections. Atterx has an IND on file with the FDA and is poised to enter Phase Ib clinical trials. Atterx’s other core technology consists of using the natural process of bacterial conjugation to treat infection. The product GN-4474 has been developed using this technology to target Gram negative bacteria.
  • Website
    http://www.atterx.com
  • Transaction Type
    Debt
  • Transaction Amount
    $700,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Proceeds purposes were not disclosed. SEC regulatory filing. Contact technology company for investment details, if applicable. Not an offer or solicitation for sale of securities.
  • M&A Terms
  • Venture Investor

Trending on Xconomy